Compare Charles River Laboratories Intl. Inc (CRL) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Vital Farms Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $226.38 (market cap $11.14B), while Vital Farms Inc trades at $13.7 (market cap $561.10M). The key difference: Charles River Laboratories Intl. Inc is far larger — about 19.9× Vital Farms Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Vital Farms Inc nearer its low. Which is the better fit depends on your goals.
| CRL | VITL | |
|---|---|---|
Market Cap | $11.14B | $561.10M |
Sector | Health | Consumer Staples |
52-Week High | $233.60 | $52.41 |
52-Week Low | $145.57 | $8.28 |
Enterprise Value | $14.00B | $563.90M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Vital Farms (VITL) trades at $12.78, down 1.31% on the day, with a bullish technical signal from moving averages and strong fundamental metrics including a 15.44% ROE and attractive valuation ratios (P/E 12.59, P/S 0.76). Recent earnings show mixed results with a Q3 2025 beat but Q1 2026 miss, while revenue grew to $759M in 2025. The stock faces headwinds from multiple class action lawsuits filed in May 2026, creating investor uncertainty despite analyst consensus favoring a buy rating.
The outlook remains cautiously optimistic with a $13.50 consensus price target offering 5.6% upside potential. Key opportunities include sustained profitability and market positioning in natural foods, while risks center on legal challenges and projected earnings volatility. Institutional sentiment leans bullish with no sell ratings, but negative cash flow trends require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
